Net Asset Value Increase
Quarterly NAV increased by $201 million vs. year-end, primarily driven by a $605 million increase in the long position in CVI.
CVI Performance and Dividend
CVI contribution up materially (driving NAV lift); company announced a $0.10 dividend and management views CVI as well positioned for potential debt reduction and shareholder returns.
Investment Funds Performance (Excluding Refining Hedges)
Investment segment returned +4.4% for the quarter excluding refining hedges; long and other positions had +4.1% attribution. Investment in the funds was approximately $2.2 billion.
Strong Portfolio Company Moves and Stock Gains
Notable portfolio company performance in Q1: AEP stock +~14% (reaffirmed 2026 outlook and raised long-term CAGR to >9%); Centuri stock +~16% (Q4 base revenue +28% and gross profit +50% and guiding strong double-digit growth); Caesars +~13%; IFF +~8%; Echostar +~8%.
Liquidity Position
Holding company had $2.8 billion in cash and investments in the funds; subsidiaries had $1.3 billion of cash and revolver availability; funds cash approx. $782 million as of quarter end.
Operational Strength in Energy and Fertilizer
Refining utilization was strong at 97%; Fertilizer segment delivered strong results driven by robust demand for spring planting, and management highlighted global tightness in refined products and nitrogen fertilizer as supportive.
Real Estate and Other Positive Segment Results
Real Estate adjusted EBITDA increased by $18 million vs. prior year quarter; Automotive same-store sales increased ~2%, indicating positive revenue trajectory in stores that remained open.
Clinical Development Progress
Pharma Transocean PAH trial preparation on schedule with first patient expected to be dosed in 60–90 days; physician community positive about potential outcomes.
Distribution Maintained
Board declared an unchanged distribution of $0.50 per depositary unit, maintaining cash return to unitholders.